Neuroinflammation and Microglial Polarity: Sirolimus Shifts Microglial Polarity to M2 phenotype in a Mouse Model of Tuberous Sclerosis Complex
Open Access
- 13 December 2022
- journal article
- research article
- Published by Scientific Archives
- Vol. 3 (2) , 63-70
Abstract
Tuberous sclerosis complex is a neurocutaneous syndrome characterized by systemic hamartomas, including skin and neural symptoms. Many patients exhibit epilepsyKeywords
This publication has 33 references indexed in Scilit:
- Sirolimus relieves seizures and neuropsychiatric symptoms via changes of microglial polarity in tuberous sclerosis complex model miceNeuropharmacology, 2022
- Uncoupling of ER/Mitochondrial Oxidative Stress in mTORC1 Hyperactivation-Associated Skin HypopigmentationJournal of Investigative Dermatology, 2018
- Everolimus for treatment of tuberous sclerosis complex‐associated neuropsychiatric disordersAnnals of Clinical and Translational Neurology, 2017
- Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled studyThe Lancet, 2016
- Involvement of P2X4 receptors in hippocampal microglial activation afterstatus epilepticusGlia, 2013
- Loss of Tsc2 in Purkinje cells is associated with autistic-like behavior in a mouse model of tuberous sclerosis complexNeurobiology of Disease, 2013
- Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complexAnnals of Neurology, 2008
- Psychiatric comorbid conditions in a clinic population of 241 patients with tuberous sclerosis complexEpilepsy & Behavior, 2007
- UDP acting at P2Y6 receptors is a mediator of microglial phagocytosisNature, 2007
- Inflammation in Neurodegenerative Disease—A Double-Edged SwordNeuron, 2002